Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Néovacs is a French biotechnology company that develops products and invests in innovative companies in Biotech and Medtech. It has distinct activities in Research and Development and investment.

msh id	COM:NEOVACS
symbol	ALNEV
name	Neovacs S.A.
homepage url	https://www.neovacs.com
country	FR
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	22
crunchbase url	-
linkedin url	-
founders	-

market cap	54.21K
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.14
growth cost of revenue	0.19
growth depreciation and amortization	3.18
growth ebitda	0.71
growth ebitda ratio	-1.61
growth eps	1
growth eps diluted	1
growth general and administrative expenses	-1
growth gross profit	-0.24
growth gross profit ratio	-10.33

COM:NEOVACS

Néovacs

Last Close

0.00

21/11 16:22

Market Cap

50.16K

Beta: -

Volume Today

52.10M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	7.32M
cost of revenue	7.32M
depreciation and amortization	4.02M
ebitda	-2.94M
ebitda ratio	-1.1K
eps	-
eps diluted	-
operating expenses	6.7M
operating income	-6.96M
operating income ratio	-2.6K

accounts receivables	-
capital expenditure	-170.14K
cash at beginning of period	17.54M
cash at end of period	46.51K
inventory	-
working capital ttm	5.17M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-